AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26067942 — intervention group
Group type: COMPARATOR
Intervention: EndoActivator irrigation
Number of subjects: 24
Study 26067942 — intervention group
Group type: COMPARATOR
Intervention: Needle irrigation
Number of subjects: 24
Study 23439274 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite vitality intervention (yoga, aerobic exercising, coaching, and fruit)
Number of subjects: 730
Study 23439274 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 730
Study 23439274 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite vitality intervention
Number of subjects: 730
Study 21239636 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose spironolactone (∼1 mg·kg(‐1)·day(‐1))
Number of subjects: 2
Study 21239636 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dose spironolactone (∼30 mg·kg(‐1)·day(‐1))
Number of subjects: 2
Study 21239636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 19892627 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenoderm
Number of subjects: 78
Study 19892627 — intervention group
Group type: COMPARATOR
Intervention: 1% silver sulfadiazine (SSD)
Number of subjects: 78
Study 16517517 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-switching paradigm in children with SLI
Number of subjects: 13
Study 16517517 — intervention group
Group type: COMPARATOR
Intervention: Task-switching paradigm in children without SLI (control group)
Number of subjects: 13
Study 14688530 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus monotherapy (n=11)
Number of subjects: 23
Study 14688530 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitors (n=12)
Number of subjects: 23
Study 10699769 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable forceps
Number of subjects: 200
Study 10699769 — intervention group
Group type: COMPARATOR
Intervention: Reusable forceps
Number of subjects: 200
Study 9315493 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride (30 mg/day, two 5 mg tablets three times daily for eight weeks)
Number of subjects: 86
Study 9315493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 9315493 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride
Number of subjects: 86
Study 7964947 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN‐gamma at a dose of 4 x 10(6) U subcutaneously per day for 6 months
Number of subjects: 100
Study 7964947 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 100
Study 7964947 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN‐gamma treatment
Number of subjects: 100
Study 3301260 — intervention group
Group type: EXPERIMENTAL
Intervention: Five bio‐ or semisynthetic human insulins (specific preparations not detailed) tested at equal dosages.
Number of subjects: 0
Study 31828805 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded breakfast service (Second Chance Breakfast)
Number of subjects: 12
Study 31828805 — intervention group
Group type: COMPARATOR
Intervention: Traditional before school cafeteria SBP service
Number of subjects: 12
Study 31828805 — intervention group
Group type: COMPARATOR
Intervention: Travel method (car, bike, walking)
Number of subjects: 12
Study 29562318 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment intervention
Number of subjects: 97
Study 29562318 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 26004041 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility training (static stretching) for 4 weeks, 4 days/week
Number of subjects: 23
Study 26004041 — intervention group
Group type: COMPARATOR
Intervention: Control group (no flexibility training)
Number of subjects: 23
Study 26004041 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility training (static stretching)
Number of subjects: 23
Study 25625966 — intervention group
Group type: EXPERIMENTAL
Intervention: Concussion (n=40)
Number of subjects: 122
Study 25625966 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI (n=41)
Number of subjects: 122
Study 25625966 — intervention group
Group type: COMPARATOR
Intervention: No diagnosis (control condition; n=41)
Number of subjects: 122
Study 23700578 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: veneer: 4% hydrofluoric acid (HF) + core: 30 µm aluminum trioxide particles coated with silica + core + veneer: silane
Number of subjects: 40
Study 23700578 — intervention group
Group type: COMPARATOR
Intervention: Group 1: veneer: 4% hydrofluoric acid (HF) + core: aluminum trioxide (50‐µm Al2O3) + core + veneer: silane
Number of subjects: 40
Study 23700578 — intervention group
Group type: COMPARATOR
Intervention: Group 2: core: Al2O3 (50 µm) + veneer: HF + core + veneer: silane
Number of subjects: 40
Study 23700578 — intervention group
Group type: COMPARATOR
Intervention: Group 4: core: 30 µm SiO2 + veneer: HF + core + veneer: silane
Number of subjects: 40
Study 20962913 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein plus carbohydrate (PRO) beverage (40 g carbohydrate, 20 g whey protein)
Number of subjects: 12
Study 20962913 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CHO) beverage (60 g)
Number of subjects: 12
Study 18641111 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (PAP)
Number of subjects: 24
Study 18641111 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 24
Study 18641111 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Bilevel PAP vs CPAP
Number of subjects: 24
Study 16858161 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg/d
Number of subjects: 60
Study 16858161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16858161 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 60
Study 16858161 — intervention group
Group type: COMPARATOR
Intervention: Flutamide and Placebo
Number of subjects: 60
Study 12873996 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGF-I levels
Number of subjects: 121
Study 12873996 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGFBP-3 levels
Number of subjects: 121
Study 12873996 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGF-I levels in cases
Number of subjects: 121
Study 12873996 — intervention group
Group type: COMPARATOR
Intervention: Serum IGF-I levels in controls
Number of subjects: 121
Study 10870746 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicinoids
Number of subjects: 0
Study 8796404 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cardiac output measurement by the Fick principle
Number of subjects: 25
Study 8796404 — intervention group
Group type: COMPARATOR
Intervention: Thermodilution cardiac output measurement
Number of subjects: 25
Study 1735847 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (Exosurf Neonatal)
Number of subjects: 30
Study 1735847 — intervention group
Group type: COMPARATOR
Intervention: Air (placebo)
Number of subjects: 30
Study 6143975 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 2 X 10(6) units IFN‐beta for 10 consecutive days
Number of subjects: 22
Study 6143975 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections for 10 consecutive days
Number of subjects: 22
Study 6143975 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐beta treatment for non-responders after 3 months
Number of subjects: 22
Study 6143975 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐beta treatment
Number of subjects: 22
Study 6143975 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections of IFN‐beta
Number of subjects: 22
Study 30681166 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser (EL)
Number of subjects: 21
Study 30681166 — intervention group
Group type: COMPARATOR
Intervention: 311-nm Titanium:Sapphire laser (TSL)
Number of subjects: 21
Study 29059367 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolism-informed care (MIC)
Number of subjects: 81
Study 29059367 — intervention group
Group type: COMPARATOR
Intervention: Guideline based care (GBC)
Number of subjects: 81
Study 26830098 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Training (SET)
Number of subjects: 40
Study 26830098 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Supervised Exercise Training (nSET)
Number of subjects: 40
Study 26830098 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 40
Study 24274379 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition (IN) with omega‐3 fatty acids, glutamine, and arginine
Number of subjects: 71
Study 24274379 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (Control)
Number of subjects: 71
Study 24274379 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition (IN)
Number of subjects: 71
Study 22227851 — intervention group
Group type: COMPARATOR
Intervention: 1,000 mL of milk
Number of subjects: 24
Study 22227851 — intervention group
Group type: COMPARATOR
Intervention: 500 mL of milk
Number of subjects: 24
Study 22227851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19606529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (80-160 mg/day)
Number of subjects: 147
Study 19606529 — intervention group
Group type: COMPARATOR
Intervention: Clozapine (250-600 mg/day)
Number of subjects: 147
Study 19606529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 147
Study 19606529 — intervention group
Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 147
Study 17891598 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 500
Study 17891598 — intervention group
Group type: COMPARATOR
Intervention: No GnRH agonist
Number of subjects: 500
Study 14713745 — intervention group
Group type: EXPERIMENTAL
Intervention: Various agents including dietary supplements, finasteride, and cyclooxygenase-2 inhibitors
Number of subjects: 11
Study 12665916 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 89
Study 12665916 — intervention group
Group type: COMPARATOR
Intervention: Interferon (IFN) alpha
Number of subjects: 89
Study 12665916 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 89
Study 9655014 — intervention group
Group type: EXPERIMENTAL
Intervention: Display duration of 20 ms
Number of subjects: 100
Study 9655014 — intervention group
Group type: EXPERIMENTAL
Intervention: Display duration of 1000 ms
Number of subjects: 100
Study 8074071 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg cholecalciferol
Number of subjects: 60
Study 8074071 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg cholecalciferol
Number of subjects: 60
Study 8074071 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg cholecalciferol every 3 months
Number of subjects: 60
Study 2684452 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous flunisolide
Number of subjects: 23
Study 2684452 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous beclomethasone dipropionate
Number of subjects: 23
Study 2684452 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 23
Study 28683004 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate/70% isopropyl alcohol (CHG/IPA) followed by gum mastic liquid adhesive (GMLA)
Number of subjects: 20
Study 28683004 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate/70% isopropyl alcohol (CHG/IPA) followed by liquid adhesive remover (LAR)
Number of subjects: 20
Study 28683004 — intervention group
Group type: COMPARATOR
Intervention: 2% chlorhexidine gluconate/70% isopropyl alcohol (CHG/IPA)
Number of subjects: 20
Study 26209025 — intervention group
Group type: EXPERIMENTAL
Intervention: It's LiFe! monitoring and feedback tool + Self‐Management Support Program (SSP)
Number of subjects: 0
Study 26209025 — intervention group
Group type: COMPARATOR
Intervention: Self‐Management Support Program (SSP)
Number of subjects: 0
Study 26209025 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 22924447 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 329
Study 22924447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 329
Study 21482217 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 10/320 mg (intensive)
Number of subjects: 728
Study 21482217 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine/valsartan 5/160 mg (moderate)
Number of subjects: 728
Study 18626761 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated video
Number of subjects: 42
Study 18626761 — intervention group
Group type: EXPERIMENTAL
Intervention: Video of self
Number of subjects: 42
Study 18626761 — intervention group
Group type: EXPERIMENTAL
Intervention: Video of a familiar person engaged with an immersive virtual reality (VR) game
Number of subjects: 42
Study 18626761 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion of self in the VR game
Number of subjects: 42
Study 17079992 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) coadministered with lopinavir/ritonavir (LPV/r)
Number of subjects: 24
Study 17079992 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) alone
Number of subjects: 24
Study 17079992 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) alone
Number of subjects: 24
Study 17079992 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) with lopinavir/ritonavir (LPV/r)
Number of subjects: 24
Study 15715034 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (two 20 min sessions per week for 16 weeks)
Number of subjects: 84
Study 15715034 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (self-administered sessions on the same schedule)
Number of subjects: 84
Study 15715034 — intervention group
Group type: COMPARATOR
Intervention: Control (standard prenatal care)
Number of subjects: 84
Study 11280830 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesilate 1 g/day continuous infusion up to postoperative day 4
Number of subjects: 50
Study 11280830 — intervention group
Group type: COMPARATOR
Intervention: Gabexate mesilate 1 g/day continuous infusion plus octreotide 0.1 mg every 8 hours for 5 days
Number of subjects: 50
Study 10322862 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongxinluo capsule (TXLC), 4 capsules, three times daily
Number of subjects: 492
Study 10322862 — intervention group
Group type: COMPARATOR
Intervention: Shuxin oral liquor (SXOL), 20 ml, two times daily
Number of subjects: 492
Study 8233513 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (VR) for 8 weeks followed by 8 weeks of home VR exercises
Number of subjects: 8
Study 8233513 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (isometric strengthening exercises) for 8 weeks followed by 8 weeks of VR
Number of subjects: 8
Study 8233513 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B) at 16-week post-test
Number of subjects: 8
Study 8233513 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported Dizziness Handicap Inventory scores
Number of subjects: 8
Study 3691557 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (A)
Number of subjects: 44
Study 3691557 — intervention group
Group type: COMPARATOR
Intervention: Control group (B)
Number of subjects: 44
Study 30157768 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 1800
Study 30157768 — intervention group
Group type: COMPARATOR
Intervention: Control group (without DM)
Number of subjects: 1800
Study 27522247 — intervention group
Group type: COMPARATOR
Intervention: Biopsy GS 6
Number of subjects: 796
Study 27522247 — intervention group
Group type: COMPARATOR
Intervention: Biopsy GS 7(-)
Number of subjects: 796
Study 27522247 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy GS 7(+)
Number of subjects: 796
Study 25479285 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging (daily for 2 weeks, alternate days for 2 weeks, weekly thereafter for 22 weeks)
Number of subjects: 303
Study 25479285 — intervention group
Group type: COMPARATOR
Intervention: No text messaging (control group)
Number of subjects: 303
Study 25479285 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging
Number of subjects: 303
Study 22715822 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% thyme essential oil antifungal cream
Number of subjects: 24
Study 22715822 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% chamomile extract cream
Number of subjects: 24
Study 22715822 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 24
Study 20028815 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine
Number of subjects: 44
Study 20028815 — intervention group
Group type: COMPARATOR
Intervention: Entecavir
Number of subjects: 44
Study 18360262 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tacrolimus exposure
Number of subjects: 92
Study 18360262 — intervention group
Group type: COMPARATOR
Intervention: Standard tacrolimus exposure
Number of subjects: 92
Study 18360262 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study 16137280 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized social activity intervention (ISAI) for 1 to 2 hours for 21 consecutive days
Number of subjects: 147
Study 12169173 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SIT) with standardized Dermatophagoides pteronyssinus extract for 3 years
Number of subjects: 29
Study 12169173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SIT)
Number of subjects: 29
Study 9926749 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside Percutaneous (BP) tracheostomy
Number of subjects: 24
Study 9926749 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside Open (BO) tracheostomy
Number of subjects: 24
Study 9926749 — intervention group
Group type: COMPARATOR
Intervention: Open tracheostomy in the operating room (OR)
Number of subjects: 24
Study 7771482 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 69
Study 7771482 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkylating agents
Number of subjects: 69
Study 7771482 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 69
Study 2297456 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg aspirin
Number of subjects: 30
Study 2297456 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg aspirin
Number of subjects: 30
Study 2297456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6153835 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid ointments (20 tested)
Number of subjects: 12
Study 6153835 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid creams (19 tested)
Number of subjects: 12
Study 6153835 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone preparations (tested with occlusion)
Number of subjects: 12
Study 6153835 — intervention group
Group type: EXPERIMENTAL
Intervention: Other corticosteroid preparations (tested with and without occlusion)
Number of subjects: 12
Study 30700068 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Therapy (ET)
Number of subjects: 51
Study 30700068 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation Therapy (MT)
Number of subjects: 51
Study 30700068 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and Manipulation Therapy (EMT)
Number of subjects: 51
Study 28658431 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position 2
Number of subjects: 33
Study 28658431 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 33
Study 28658431 — intervention group
Group type: COMPARATOR
Intervention: Other positions (Fowler's, supine, left lateral)
Number of subjects: 33
Study 26071836 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC) with 3 cycles of 5-minute inflation to 200 mmHg
Number of subjects: 20
Study 26071836 — intervention group
Group type: COMPARATOR
Intervention: Control procedure with 3 cycles of 5-minute inflation to 10 mmHg
Number of subjects: 20
Study 26071836 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPC and Control procedures
Number of subjects: 20
Study 24913818 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprout beverage providing daily doses of 600 μmol glucoraphanin and 40 μmol sulforaphane
Number of subjects: 291
Study 24913818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 22368023 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted radical gastrectomy (LAG group)
Number of subjects: 255
Study 22368023 — intervention group
Group type: COMPARATOR
Intervention: Conventional open gastrectomy (OG group)
Number of subjects: 255
Study 19729908 — intervention group
Group type: EXPERIMENTAL
Intervention: High cut-off (HCO) membranes
Number of subjects: 8
Study 19729908 — intervention group
Group type: COMPARATOR
Intervention: High-flux membranes
Number of subjects: 8
Study 18090001 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low‐flow hemofiltration (n = 8) or hemodiafiltration (n = 11)
Number of subjects: 19
Study 16054252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial acetylcholine
Number of subjects: 63
Study 16054252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial nitroprusside
Number of subjects: 63
Study 16054252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio between acetylcholine and nitroprusside
Number of subjects: 63
Study 16054252 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly group
Number of subjects: 63
Study 16054252 — intervention group
Group type: COMPARATOR
Intervention: Atherosclerotic vascular disease group
Number of subjects: 63
Study 14760893 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir/nevirapine (1250/200 mg twice daily)
Number of subjects: 233
Study 14760893 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir/saquinavir (400/400 mg twice daily)
Number of subjects: 233
Study 10643677 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (60% of energy fat)
Number of subjects: 27
Study 10643677 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat diet (30% of energy fat)
Number of subjects: 27